This item is authorised by the following title:
For a transitional provision relating to the repeal of this instrument, see section 38 of the National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021).
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2021 (No. 2) (PB 17 of 2021)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2021 (No. 1) (PB 4 of 2021)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 11) (PB 129 of 2020)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 10) (PB 115 of 2020)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 9) (PB 106 of 2020)
National Health Legislation Amendment (Listing of Pharmaceutical Benefits for Supply Only) Instrument 2020 (PB 109 of 2020)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 8) (PB 93 of 2020)
National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No. 2) (PB 100 of 2020)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 7) (PB 82 of 2020)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 6) (PB 72 of 2020)
National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2020 (No. 5) (PB 46 of 2020)
For a transitional provision relating to the repeal of this instrument, see section 38 of the National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021).